US › Healthcare

Vaxart Inc (VXRT)

US · Healthcare · Biotechnology

$0.490.00%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$27.2M

Revenue YoY

-31.6%

Net profit

$-13.5M

EPS

$-0.06

EPS estimate

$-0.21

Net margin

-49.6%

EPS came in at -0.06 against a street estimate of -0.21 — a beat of 71.4%.

Key statistics

Market cap

$119.2M

P/E

2.9

Forward P/E

42.7

P/B

1.43

Book value

$0.39

EPS (TTM)

$0.17

52-week high

$0.84

52-week low

$0.31

50-day MA

$0.53

200-day MA

$0.58

Beta

1.06

Analyst view

Analysts rate Vaxart Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $3.33.

Shareholding

Insiders

1.43%

Institutions

0.05%

Largest institutional holders

Fund	Stake
Heritage Wealth Advisors, LLC	0.01%
LVM Capital Management Ltd.	0.01%
Kingswood Wealth Advisors LLC	0.00%
Golden State Equity Partners	0.00%
Archer Investment Corporation	0.00%
First Command Advisory Services, Inc.	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vaxart Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.